Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Insider Sells 2,804 Shares

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) insider Tsveta Milanova sold 2,804 shares of the stock in a transaction on Monday, January 6th. The shares were sold at an average price of $32.18, for a total value of $90,232.72. Following the completion of the transaction, the insider now directly owns 18,906 shares in the company, valued at $608,395.08. This trade represents a 12.92 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Agios Pharmaceuticals Stock Performance

AGIO traded up $1.58 on Tuesday, hitting $35.12. 1,196,971 shares of the company were exchanged, compared to its average volume of 1,247,393. Agios Pharmaceuticals, Inc. has a fifty-two week low of $20.96 and a fifty-two week high of $62.58. The firm has a market capitalization of $2.00 billion, a P/E ratio of 3.09 and a beta of 0.87. The business’s fifty day moving average is $47.38 and its 200 day moving average is $45.70.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on AGIO shares. Leerink Partnrs downgraded shares of Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 27th. Royal Bank of Canada boosted their price objective on Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. Raymond James restated an “outperform” rating and set a $51.00 target price on shares of Agios Pharmaceuticals in a research report on Thursday, October 10th. Leerink Partners lowered shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $60.00 to $56.00 in a research note on Friday, September 27th. Finally, StockNews.com raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 9th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $56.33.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Nordea Investment Management AB boosted its position in Agios Pharmaceuticals by 3.6% during the fourth quarter. Nordea Investment Management AB now owns 220,569 shares of the biopharmaceutical company’s stock worth $7,191,000 after acquiring an additional 7,593 shares during the last quarter. Exome Asset Management LLC acquired a new position in Agios Pharmaceuticals in the third quarter valued at $2,941,000. Franklin Resources Inc. acquired a new stake in Agios Pharmaceuticals in the 3rd quarter worth about $1,499,000. Geode Capital Management LLC grew its holdings in Agios Pharmaceuticals by 0.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,357,531 shares of the biopharmaceutical company’s stock valued at $60,326,000 after buying an additional 6,101 shares during the period. Finally, Frazier Life Sciences Management L.P. increased its stake in shares of Agios Pharmaceuticals by 19.7% during the 3rd quarter. Frazier Life Sciences Management L.P. now owns 1,044,154 shares of the biopharmaceutical company’s stock valued at $46,392,000 after acquiring an additional 172,180 shares during the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.